Company intelligence / Profile preview

FoxHollow Technologies

Redwood City, California, United Statesbloomberg.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company developed and commercialized the SilverHawk Plaque Excision System for atherectomy in peripheral arterial disease. The system received FDA approval in 2003 and was used widely before the company was acquired by ev3 in 2007. Clinical data at the time of acquisition were limited but the technology was considered innovative for minimally invasive removal of atherosclerotic plaque.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Merck & Co. held an equity stake and had a collaboration agreement on analysis of atherosclerotic plaque

Beyond the preview

Go deeper on FoxHollow Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FoxHollow Technologies.

Explore the full profile